EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review

Raimon Sanmartí, Hèctor Corominas iD

Journal of Clinical Medicine · 21.02.2023 · 12 (5) · 1734

DOI: 10.3390/jcm12051734 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.02.2023. Verfasst von Raimon Sanmartí und 1 weiteren Autor:innen. Beteiligte Einrichtung: Arthritis Unit Rheumatology Service, Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), 08036 Barcelo…. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie (Spain), AbbVie company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor recently approved by the European Medicine Agency and the Food and Drug Administration for the treatment of rheumatoid arthritis (RA) at a dose of 15 mg/day. We present the chemical structure and mechanism of action of upadacitinib together with a comprehensive review of the efficacy of this drug in RA based on the SELECT clinical trial program and its safety profile. Its role in the management and therapeutic strategy of RA is also discussed. Upadacitinib in the different clinical trials has shown similar rates of clinical response, including the remission rates, regardless of the population analyzed (methotrexate-naïve, methotrexate-failure or biologic failure). In a head-to-head randomized clinical trial, upadacitinib plus methotrexate was superior to adalimumab when given on background methotrexate (MTX) in patients who have experienced an inadequate response to MTX. Upadacitinib also demonstrated superiority over abatacept in patients with RA after failure to previous biologic drugs. The safety profile of upadacitinib is generally consistent with those observed with biological or other JAK inhibitors.

Schlagwörter

Stichwörter der Autor:innen

Janus kinase inhibitorsefficacyreviewrheumatoid arthritissafetyupadacitinib

Autor:innen und Institutionen

  • Arthritis Unit Rheumatology Service, Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), 08036 Barcelona, Spain.
  • Servei de Reumatologia, Hospital Universitari de Sant Pau, 08025 Barcelona, Spain.
  • Servei de Reumatologia, Hospital Dos de Maig, 08025 Barcelona, Spain.

ORCID-Profile: Hèctor Corominas

Förderung

  • AbbVie (Spain)
  • AbbVie company

Zitieren

APA

Sanmartí, R., & Corominas, H. (2023). Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review. Journal of Clinical Medicine, 12(5), 1734. https://doi.org/10.3390/jcm12051734

Vancouver

Sanmartí R, Corominas H. Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review. Journal of Clinical Medicine. 2023;12(5):1734. doi:10.3390/jcm12051734

BibTeX
@article{Sanmart2023,
  author = {Sanmartí, Raimon and Corominas, Hèctor},
  title = {Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {5},
  pages = {1734},
  doi = {10.3390/jcm12051734}
}
Kostenlos starten →